Associated Papers
Computational modeling of human genetic variants in mice.
Dong K et al.
Biorxiv : the Preprint Server for Biology, 2025
40060429 (PubMed )
Supplement: media-1.zip › Supp_Data_6_KIT_pathogenecity.xlsx › Sheet1_AlphaMissense
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
39063150 (PubMed )
Supplement: ijms-25-07908-s001.zip › ijms-3103240-supplementary.pdf
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.
Ong HW et al.
Acs Chemical Neuroscience, 2023
37084253 (PubMed )
Supplement: cn3c00135_si_001.pdf
A full-proteome, interaction-specific characterization of mutational hotspots across human cancers.
Chen S et al.
Genome Research, 2022
34963661 (PubMed )
Supplement: supp_gr.275437.121_Supplementary_Table_1.xlsx › Non-recurrent_variants
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Identification of candidate genes for lung cancer somatic mutation test kits.
Chen Y et al.
Genetics and Molecular Biology, 2013
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer (amsterdam, Netherlands), 2008
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ et al.
The New England Journal of Medicine, 2004
Select a paper to view details